HIV-Positive Patients Faced Longer Travel for Cancer Trials
New research shows that limited trial options force HIV-positive patients to travel significantly further for CAR-T therapy.
Updated on Sept. 30, 2026 in Cancer
Live Poll
Should federal healthcare policy prioritize expanding clinical trial access in underserved geographic regions?
Researchers found that HIV-positive cancer patients must travel longer distances to access CAR-T clinical trials compared to patients in standard trials. This disparity is particularly pronounced in the US South, where geographic and exclusionary barriers restrict care access.
Why it matters
Limited trial eligibility restricts access to emerging cancer treatments for HIV-positive individuals, creating a significant barrier to equitable care. These findings highlight how trial design choices directly impact a patient's ability to receive potentially life-saving therapies.
A geospatial analysis of 80 interventional CAR-T trials in the US found that 72.5% of studies explicitly exclude people living with HIV, while only 13.8% include them. This exclusion results in a national median travel time of 1.15 hours for inclusive trials versus 0.84 hours for others.
The players
National Institutes of Health
The nation's primary medical research agency that maintains the federal clinical trials database.
The details
Researchers used mapping tools to calculate travel times by analyzing the National Institutes of Health's clinical trials database for non-Hodgkin lymphoma CAR-T therapies. By comparing trial locations against participant proximity, the study identified that patients in the US South face the most significant travel burden at 1.70 hours. The research confirms that trial eligibility criteria serve as a structural barrier that intersects with socioeconomic status to further limit access for marginalized populations.
Timeline
September 30, 2026: Study findings on CAR-T access were published.
Health Landscape
This research utilizes the National Institutes of Health's clinical trials database to quantify how historic exclusion criteria continue to shape modern oncology research. It identifies a clear need for broader inclusion standards to align clinical trial access with the demographics of the patient population.
Patients and their families should discuss potential trial eligibility with their oncology team to identify local versus regional options for advanced therapies. Those living in areas with fewer inclusive trials may wish to ask their physician about remote monitoring or travel assistance programs.
The takeaway
Geographic barriers to clinical trials are not just logistical challenges but are deeply rooted in restrictive study eligibility criteria. Patients should keep this information in mind when consulting with a doctor about trial opportunities, specifically asking if a trial excludes certain health conditions.
Further reading
Learn more about the evolving landscape of Cancer treatment and research access in the United States.
Source note: This article includes information reported by Notre Dame News.
Live Poll
Should federal healthcare policy prioritize expanding clinical trial access in underserved geographic regions?
